Modern concepts of preeclampsia: A literature review
DOI:
https://doi.org/10.37800/RM.2.2026.711Keywords:
preeclampsia, placental dysfunction, PlGF, sFlt-1/PlGF ratio, first trimester assessment, angiogenic markers, personalized prevention, pregnancyAbstract
Relevance: Preeclampsia is a major pregnancy complication and a leading global cause of maternal and perinatal morbidity and mortality. Despite extensive research, its pathogenesis remains complex and multifactorial. Recent perspectives define preeclampsia as a heterogeneous disorder involving immunological and genetic factors, abnormal placentation, and endothelial dysfunction. The introduction of angiogenic biomarkers and integrated first-trimester risk models has significantly improved early prediction and prevention; however, challenges remain in their standardized clinical application.
The study aimed to synthesize recent evidence on the pathophysiology, risk factors, early prediction, diagnosis, and prevention of preeclampsia.
Materials and Methods: A literature review of studies published between 2015 and 2025 was conducted, including original articles, cohort studies, meta-analyses, and reviews. The analysis focused on etiology, clinical risk factors, angiogenic biomarkers, first-trimester screening, and preventive strategies. A qualitative thematic synthesis was conducted to address placental remodeling, angiogenic imbalance, immune-inflammatory mechanisms, epigenetics, and personalized approaches.
Results: Impaired spiral artery remodeling and placental ischemia are central to preeclampsia pathogenesis, leading to angiogenic imbalance (increased sFlt-1, decreased PlGF) and systemic endothelial dysfunction. Genetic, metabolic, and clinical risk factors further contribute to disease development. Integrated first-trimester screening combining biochemical markers, ultrasound, and clinical data provides the most effective early risk assessment. PlGF levels and the sFlt-1/PlGF ratio are valuable tools for diagnosis and monitoring. Emerging approaches, including microRNA profiling, cfDNA methylation, and polygenic risk models, show promising potential.
Conclusion: Preeclampsia is a multifactorial disorder with diverse clinicopathogenetic phenotypes. Integration of first-trimester screening and angiogenic biomarkers improves predictive accuracy and enables personalized management. Molecular prediction methods are перспективны, but require standardization and validation. A history of preeclampsia is associated with increased long-term cardiovascular risk, necessitating prolonged follow-up.
References
1. Orabona R, Sciatti E, Sartori E, Vizzardi E, Prefumo F. The impact of preeclampsia on women’s health: cardiovascular long-term implications. Obstet Gynecol Surv. 2020;75(11):703-709. https://doi.org/10.1097/OGX.0000000000000846
2. Yang C, Baker PN, Granger JP, Davidge ST, Tong C. Long-term impacts of preeclampsia on the cardiovascular system of mother and offspring. Hypertension. 2023;80(9):1821-1833.
https://doi.org/10.1161/HYpreeclampsiaRTENSIONAHA.123.21061
3. Roberts JM. Preeclampsia epidemiology(ies) and pathophysiology(ies). Best Pract Res Clin Obstet Gynaecol. 2024;94:102480.
https://doi.org/10.1016/j.bpobgyn.2024.102480
4. Yagel S, Cohen SM, Admati I, Skarbianskis N, Solt I, Zeisel A, Beharier O, Goldman-Wohl D. Expert review: preeclampsia Type I and Type II. Am J Obstet Gynecol MFM. 2023;5(12):101203.
https://doi.org/10.1016/j.ajogmf.2023.101203
5. Lai J, Syngelaki A, Nicolaides KH, von Dadelszen P, Magee LA. Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes. Am J Obstet Gynecol. 2021;224(5):518.e1-518.e11.
https://doi.org/10.1016/j.ajog.2020.11.004
6. Brosens I, Puttemans P, Benagiano G. Placental bed research: I. The placental bed: from spiral arteries remodeling to the great obstetrical syndromes. Am J Obstet Gynecol. 2019;221(5):437-456.
https://doi.org/10.1016/j.ajog.2019.05.044
7. Staff AC, Fjeldstad HE, Fosheim IK, Moe K, Turowski G, Johnsen GM, Alnaes-Katjavivi P, Sugulle M. Failure of physiological transformation and spiral artery atherosis: their roles in preeclampsia. Am J Obstet Gynecol. 2022;226(2):S895-S906.
https://doi.org/10.1016/j.ajog.2020.09.026
8. Stepan H, Galindo A, Hund M, Schlembach D, Sillman J, Surbek D, Vatish M. Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of preeclampsia and fetal growth restriction. Ultrasound Obstet Gynecol. 2023;61(2):168-180.
https://doi.org/10.1002/uog.26032
9. Chaemsaithong P, Sahota DS, Poon LC. First trimester preeclampsia screening and prediction. Am J Obstet Gynecol. 2022;226(2):S1071-S1097.e2.
https://doi.org/10.1016/j.ajog.2020.07.020
10. de Borre M, Che H, Yu Q, Lannoo L, de Ridder K, Vancoillie L, Dreesen P, van den Ackerveken M, Aerden M, Galle E, Breckpot J, van Keirsbilck J, Gyselaers W, Devriendt K, Vermeesch JR, van Calsteren K, Thienpont B. Cell-free DNA methylome analysis for early preeclampsia prediction. Nat Med. 2023;29(9):2206-2215.
https://doi.org/10.1038/s41591-023-02510-5
11. Honigberg MC, Truong B, Khan RR, Xiao B, Bhatta L, Vy HMT, Guerrero RF, Schuermans A, Selvaraj MS, Patel AP, Koyama S, Cho SMJ, Vellarikkal SK, Trinder M, Urbut SM, Gray KJ, Brumpton BM, Patil S, Zöllner S, Antopia MC, Saxena R, Nadkarni GN, Do R, Yan Q, Pe'er I, Verma SS, Gupta RM, Haas DM, Martin HC, van Heel DA, Laisk T, Natarajan P. Polygenic prediction of preeclampsia and gestational hypertension. Nat Med. 2023;29(6):1540-1549.
https://doi.org/10.1038/s41591-023-02374-9
12. Jung E, Romero R, Yeo L, Gomez-Lopez N, Chaemsaithong P, Jaovisidha A, Gotsch F, Erez O. The etiology of preeclampsia. Am J Obstet Gynecol. 2022;226(2):S844-S866.
https://doi.org/10.1016/j.ajog.2021.11.1356
13. Hu X, Zhang L. Uteroplacental circulation in normal pregnancy and preeclampsia: functional adaptation and maladaptation. Int J Mol Sci. 2021;22(16):8622.
https://doi.org/10.3390/ijms22168622
14. Hong K, Park HJ, Cha DH. Clinical implications of placenta-derived angiogenic/anti-angiogenic biomarkers in preeclampsia. Biomark Med. 2021;15(7):523-536.
https://doi.org/10.2217/bmm-2020-0545
15. Zeisler H, Llurba E, Chantraine FJ, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Schoedl M, Grill S, Hund M, Verlohren S. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting. Ultrasound Obstet Gynecol. 2019;53(3):367-375.
https://doi.org/10.1002/uog.19178
16. Collier A, Smith LA, Karumanchi SA. Review of the immune mechanisms of preeclampsia and the potential of immune modulating therapy. Hum Immunol. 2021;82(5):362-370. https://doi.org/10.1016/j.humimm.2021.01.004
17. Miller D, Motomura K, Galaz J, Gershater M, Lee ED, Romero R, Gomez-Lopez N. Cellular immune responses in the pathophysiology of preeclampsia. J Leukoc Biol. 2022;111(1):237-260. Epub 2021.
https://doi.org/10.1002/jlb.5ru1120-787rr
18. Javandoust Gharehbagh F, Soltani-Zangbar MS, Yousefzadeh Y. Immunological mechanisms in preeclampsia: a narrative review. J Reprod Immunol. 2024;164:104282. https://doi.org/10.1016/j.jri.2024.104282
19. Wang Y, Li B, Zhao Y. Inflammation in preeclampsia: genetic biomarkers, mechanisms, and therapeutic strategies. Front Immunol. 2022;13:883404.
https://doi.org/10.3389/fimmu.2022.883404
20. Ashraf UM, Hall DL, Rawls AZ, Alexander BT. Epigenetic processes during preeclampsia and effects on fetal development and chronic health. Clin Sci (Lond). 2021;135(19):2307-2327. https://doi.org/10.1042/CS20190070
21. Caniçais C, Vasconcelos S, Ramalho C, Marques CJ, Dória S. Deregulation of imprinted genes expression and epigenetic regulators in placental tissue from intrauterine growth restriction. J Assist Reprod Genet. 2021;38(4):791-801.
https://doi.org/10.1007/s10815-020-02047-3
22. Kosmuratova ShB, Bitemirova ShK, Zhakieva ShS, Zhylkaidar GM, Kaysazhanova GA. Clinical and anamnestic risk factors for developing preeclampsia. Reprod Med (Central Asia). 2024;2:80-87.
https://doi.org/10.37800/RM.2.2024.80-87
23. Karataeva SK, Orynbek BA, Pankova AN, Khanazarova AE, Kenzhaeva D. Maternal obesity and placental pathology: a prospective cohort study of pregnancy outcomes. Reprod Med (Central Asia). 2025;2:126-132.
https://doi.org/10.37800/RM.2.2025.506
24. Wu L, Chen Y, Guan X, Tong J, Wu X, Niu J. [Associations between pre-pregnancy body mass index and occurrence and clinical features of preeclampsia]. Zhonghua Fu Chan Ke Za Zhi. 2021;56(2):96-101.
https://doi.org/10.3760/cma.j.cn112141-20200904-00691
25. Li F, Wang T, Chen L, Zhang S, Chen L, Qin J. Adverse pregnancy outcomes among mothers with hypertensive disorders in pregnancy: a meta-analysis of cohort studies. Pregnancy Hypertens. 2021;24:107-117.
https://doi.org/10.1016/j.preghy.2021.03.001
26. Kivioja A, Toivonen E, Tyrmi J, Ruotsalainen S, Ripatti S, Huhtala H, Jääskeläinen T, Heinonen S, Kajantie E, Kere J, Kivinen K, Pouta A, Saarela T, Laivuori H. Increased risk of preeclampsia in women with a genetic predisposition to elevated blood pressure. Hypertension. 2022;79(9):2008-2015.
https://doi.org/10.1161/HYpreeclampsiaRTENSIONAHA.122.18996
27. Tyrmi JS, Kaartokallio T, Lokki AI, Jääskeläinen T, Kortelainen E, Ruotsalainen S, Karjalainen J, Ripatti S, Kivioja A, Laisk T, Kettunen J, Pouta A, Kivinen K, Kajantie E, Heinonen S, Kere J, Laivuori H; FINNPEC Study Group, FinnGen Project, and the Estonian Biobank Research Team. Genetic risk factors associated with preeclampsia and hypertensive disorders of pregnancy. JAMA Cardiol. 2023;8(7):674-683.
https://doi.org/10.1001/jamacardio.2023.1312
28. Allotey J, Archer L, Coomar D, Snell KI, Smuk M, Oakey L, Haqnawaz S, Betrán AP, Chappell LC, Ganzevoort W, Gordijn S, Khalil A, Mol BW, Morris RK, Myers J, Papageorghiou AT, Thilaganathan B, Da Silva Costa F, Facchinetti F, Coomarasamy A, Ohkuchi A, Eskild A, Arenas Ramírez J, Galindo A, Herraiz I, Prefumo F, Saito S, Sletner L, Cecatti JG, Gabbay-Benziv R, Goffinet F, Baschat AA, Souza RT, Mone F, Farrar D, Heinonen S, Salvesen KÅ, Smits LJ, Bhattacharya S, Nagata C, Takeda S, van Gelder MM, Anggraini D, Yeo S, West J, Zamora J, Mistry H, Riley RD, Thangaratinam S. Validation and development of models using clinical, biochemical and ultrasound markers for predicting preeclampsia: an individual participant data meta-analysis. Health Technol Assess. 2020;24(72):1-290.
https://doi.org/10.3310/hta24720
29. Chaemsaithong P, Pooh RK, Zheng M, Ma R, Chaiyasit N, Tokunaka M, Shaw SW, Seshadri S, Choolani M, Wataganara T, Yeo GSH, Wright A, Leung WC, Sekizawa A, Hu Y, Naruse K, Saito S, Sahota D, Leung TY, Poon LC. Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population. Am J Obstet Gynecol. 2019;221(6):650.e1-650.e16.
https://doi.org/10.1016/j.ajog.2019.09.041
30. Cuenca-Gómez D, de Paco Matallana C, Rolle V, Mendoza M, Valiño N, Revello R, Adiego B, Casanova MC, Molina FS, Delgado JL, Wright A, Figueras F, Nicolaides KH, Santacruz B, Gil MM. Comparison of different methods of first-trimester screening for preterm preeclampsia: cohort study. Ultrasound Obstet Gynecol. 2024;64(1):57-64.
https://doi.org/10.1002/uog.27622
31. Mazer Zumaeta A, Wright A, Syngelaki A, Maritsa VA, da Silva AB, Nicolaides KH. Screening for pre-eclampsia at 11-13 weeks’ gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both. Ultrasound Obstet Gynecol. 2020;56(3):400-407. https://doi.org/10.1002/uog.22093
32. Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, Shennan AH, Chappell LC, Bahl R, Bambridge G, Barnfield S, Ficquet J, Gill C, Girling J, Harding K, Khalil A, Sharp A, Simpson N, Tuffnell D. Placental growth factor testing to assess women with suspected preeclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet. 2019;393(10183):1807-1818.
https://doi.org/10.1016/S0140-6736(18)33212-4
33. Duhig KE, Webster LM, Sharp A, Gill C, Seed PT, Shennan AH, Myers JE, Chappell LC. Diagnostic accuracy of repeat placental growth factor measurements in women with suspected preeclampsia: a case series study. Acta Obstet Gynecol Scand. 2020;99(8):994-1002. https://doi.org/10.1111/aogs.13818
34. Hurrell A, Sparkes J, Duhig K, Seed PT, Myers J, Battersby C, Clark K, Green M, Hunter RM, Shennan AH, Chappell LC, Webster L. Placental growth fActor repeat sampling for reduction of adverse perinatal outcomes in women with suspecTed preeclampsia: study protocol for a randomised controlled trial (PARROT-2). Trials. 2022;23(1):792.
https://doi.org/10.1186/s13063-022-06652-8
35. Binder J, Palmrich P, Kalafat E, Haberl C, Schirwani N, Pateisky P, Khalil A. Longitudinal assessment of angiogenic markers in prediction of adverse outcome in women with confirmed preeclampsia. Ultrasound Obstet Gynecol. 2023;62(6):843-851.
https://doi.org/10.1002/uog.26276
36. Binder J, Kalafat E, Palmrich P, Pateisky P, Khalil A. Should angiogenic markers be included in diagnostic criteria of superimposed pre-eclampsia in women with chronic hypertension? Ultrasound Obstet Gynecol. 2022;59(2):192-201.
https://doi.org/10.1002/uog.23711
37. McCarthy FP, Gill C, Seed PT, Bramham K, Chappell LC, Shennan AH. Comparison of three commercially available placental growth factor-based tests in women with suspected preterm pre-eclampsia: the COMPARE study. Ultrasound Obstet Gynecol. 2019;53(1):62-67. https://doi.org/10.1002/uog.19051
38. Hurrell A, Beardmore-Gray A, Duhig K, Webster L, Chappell LC, Shennan AH. Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation. BJOG. 2020;127(13):1590-1597.
https://doi.org/10.1111/1471-0528.16425
39. Космуратова Ш., Аязбаева Л., Алиева К., Досимбетов М. Қан мен зәрдегі плацентарлы өсу факторының деңгейі және босану нәтижесі арасындағы байланыс: клиникалық сынақ. Репродуктивті медицина (Орталық Азия). 2025;1:102-107.
Kosmuratova Sh.B, Ayazbaeva L.K, Alieva K.B, Dossimbetova M.B.. Relationship between blood and urine placental growth factor levels and pregnancy outcome: clinical research. Reprod Med (Central Asia). 2025;1:102-107. Kazakh.
https://doi.org/10.37800/RM.1.2025.394
40. Chantanavilai S, Kongwattanakul K, Komwilaisak R, Saksiriwuttho P, Chaiyarach S, Duangkam C, Hayakungchat S, Thepsuthammarat K. Epidemiology and prognostic factors for successful expectant management of early-onset severe features preeclampsia: a retrospective multicenter cohort study. Pregnancy Hypertens. 2022;30:226-231.
https://doi.org/10.1016/j.preghy.2022.11.003
41. Duhig K, Seed PT, Placzek A, Sparkes J, Gill C, Brockbank A, Shennan A, Thangaratinam S, Chappell LC. A prognostic model to guide decision-making on timing of delivery in late preterm preeclampsia: the preeclampsia: the PEACOCK prospective cohort study. Health Technol Assess. 2021;25(30):1-25.
https://doi.org/10.3310/hta25300
42. Kurmanova A, Salimbayeva D, Mamedalieva N, Urazbayeva G, Terlikbayeva A, Kypshakbayeva Zh, Smailov M. Modern approaches to the prevention of hypertensive conditions during pregnancy: a literature review. Reprod Med. 2023;(4):41-48.
https://doi.org/10.37800/RM.4.2023.37-42
43. Alipova G, Ablakimova N, Tussupkaliyeva K, Bermagambetova S, Kosmuratova S, Karimsakova B, Gaiday A, Gaiday A, Dinets A, Tussupkaliyev A. Prevention of preeclampsia: modern strategies and the role of early screening. J Clin Med. 2025;14(9):2970.
https://doi.org/10.3390/jcm14092970
44. Johnson JM, Walsh JD, Okun NB, Metcalfe A, Pastuck ML, Maxey CM, Soliman N, Mahallati H, Kuret VH, Dwinnell SJ, Chada R, O’Quinn CP, Schacher J, Somerset DA, Paterson K, Suchet IB, Silang KA, Paul H, Nerenberg KA, Johnson DW. The implementation of preeclampsia screening and prevention (IMPRESS) study. Am J Obstet Gynecol MFM. 2023;5(2):100815. https://doi.org/10.1016/j.ajogmf.2022.100815
45. Safarova KT, Omertaeva DE, Mugazov MM, Amirbekova ZhT, Uvasheva AD, Akzhol GA. The influence of the maternal microbiome on the development of preeclampsia: a literature review. Reprod Med (Central Asia). 2024;1:44-51.
https://doi.org/10.37800/RM.1.2024.44-51
46. Ali A, Hadlich F, Abbas MW, Iqbal MA, Tesfaye D, Bouma GJ, Winger QA, Ponsuksili S. MicroRNA-mRNA networks in pregnancy complications: a comprehensive downstream analysis of potential biomarkers. Int J Mol Sci. 2021;22(5):2313.
https://doi.org/10.3390/ijms22052313
47. Hornakova A, Kolkova Z, Holubekova V, Loderer D, Lasabova Z, Biringer K, Halasova E. Diagnostic potential of microRNAs as biomarkers in the detection of preeclampsia. Genet Test Mol Biomarkers. 2020;24(6):321-327.
https://doi.org/10.1089/gtmb.2019.0264
48. Kukor Z. Nutrigenetic investigations in preeclampsia. Nutrients. 2024;16(19):3248.
https://doi.org/10.3390/nu16193248
49. Kongwattanakul K, Saksiriwuttho P, Chaiyarach S, Thepsuthammarat K. Incidence, characteristics, maternal complications, and perinatal outcomes associated with preeclampsia with severe features and HELLP syndrome. Int J Womens Health. 2018;10:371-377.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ш.Б. Космуратова, Ж.А Казангапова, А.А. Бектанова, Г.Е. Кузденбаева , Г.М. Жылқайдар , A.E. Узакбаева
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The articles published in this Journal are licensed under the CC BY-NC-ND 4.0 (Creative Commons Attribution – Non-Commercial – No Derivatives 4.0 International) license, which provides for their non-commercial use only. Under this license, users have the right to copy and distribute the material in copyright but are not permitted to modify or use it for commercial purposes. Full details on the licensing are available at https://creativecommons.org/licenses/by-nc-nd/4.0/.
